Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients

Journal of Acquired Immune Deficiency Syndromes

Volumn 33, Issue 1, 2003, Pages 29-33

  John, Mina ^a   McKinnon, Elizabeth J ^a   James, Ian R ^a   Nolan, David A ^a   Herrmann, Susan E ^a   Moore, Corey B ^a   White, Alex J ^b   Mallal, Simon A ^a,c  

^a MURDOCH UNIVERSITY   (Australia)

^b GLAXOSMITHKLINE   (United Kingdom)

^c ROYAL PERTH HOSPITAL   (Australia)

Author keywords

Abacavir; Combivir; HAART; Lipoatrophy; Switching study

Indexed keywords

ABACAVIR; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NELFINAVIR; PROTEINASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; BODY FAT; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INDUCED DISEASE; DUAL ENERGY X RAY ABSORPTIOMETRY; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPID BLOOD LEVEL; LIPOATROPHY; MALE; METABOLIC PARAMETERS; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; VIRUS LOAD;

EID: 0038034454     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200305010-00005     Document Type: Article

References (11)

1. Mallal S, John M, Moore C, et al. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in HIV infection. AIDS. 2000;14:1309-1316.
2. John M, Nolan D, Mallal S. Antiretroviral therapy and the lipodystrophy syndrome (review). Antiviral Ther. 2001;6:9-20.
3. Negredo E, Cruz L, Paredes R, et al. Virological, immunological and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression. Clin Infect Dis. 2002;34:504-510.
4. Rozenbaum W, Molina JM, Delfraissy JF, et al. Improvement of lipodystrophy in HIV-infected subjects switching from 2 NRTI/PI to 2 NRTI/abacavir (French substudy, CNA30017) [abstract 47]. 7th Conference on Retroviruses and Opportunistic Infections, January 30-February 2 2000, San Francisco, CA.
5. Carr A, Hudson J, Chuah J, et al. HIV protease inhibitor substitution in patients with lipodystrophy: randomised, controlled, openlabel, multicentre study. AIDS. 2001;15:1811-1822.
6. Carr A, Workman C, Smith D, et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy. JAMA. 2002; 288:207-215.
7. McComsey G, Ward D, Hessenthaler S, et al. CT scan findings at 48 weeks confirm further regression of lipoatrophy following substitution of stavudine (d4T) with either abacavir (ABC) or zidovudine (ZDV) [abstract H-1929]. 42nd Conference on Antimicrobial Agents and Chemotherapy, September 27-30 2002, San Diego, CA.
8. Saint Marc T, Touraine JL. The effects of discontinuing stavudine therapy on clinical and metabolic abnormalities in patients suffering from lipodystrophy. AIDS. 1999;13:2188-2189.
9. Saint Marc T, Partisani M, Poizot-Martin I, et al. Reversibility of peripheral fat wasting (lipoatrophy) on stopping stavudine therapy [abstract 52]. 7th Conference on Retroviruses and Opportunistic Infections, January 30-February 2 2000, San Francisco, CA.
10. Dube MP, Zackin R, Tebas P, et al. Prospective study of regional body composition in antiretroviral-naive subjects randomized to receive zidovudine + lamivudine or stavudine + didanosine combined with nelfinavir, efavirenz, or both [abstract 27]. A50055, a substudy of ACTG 384. Antiviral Ther. 2002;7:48.
11. Moyle GJ, Baldwin C, Langroudi B, et al. A 48-week, randomized open-label comparison of 3 abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy. J Acquir Immune Defic Syndr. 2003;in press.